Slope Expands Go-To-Market Team for its eClinical Supply Chain Management Platform with Two Industry Veterans

Ben Carmel as Chief Revenue Officer and Matt Smith as VP Research Site Development, Will Help the Clinical Trial Industry Strengthen Clinical Supply Management for Complex Clinical Trials

Slope, provider of the first eClinical Supply Chain Management (eCSCM) platform, announced hiring two leaders with deep clinical trial expertise: Ben Carmel as Chief Revenue Officer and Matt Smith as Research Site Development Vice President.

In his new role, Ben will engage with clinical trial sponsors and contract research organizations (CROs) to reduce clinical trial risks, rein in costs, improve the productivity of clinical trial collaborators, and increase subject enrollment and retention by moving the manual and error-prone processes used to manage and track clinical supplies and biological samples to a digital platform.

Matt will engage with top academic research centers (AMCs) and clinical research sites to raise awareness and adoption of the Slope eCSCM platform. AMCs and clinical research sites use a free version of Slope to manage their clinical supply inventory—lab kits, investigational products (IP), devices, ancillary clinical supplies, and biological samples—so they are prepared for every subject procedure and never lose a sample.

“There is a disconnect in the industry between how clinical research sites are expected to manage their clinical supply inventory and the tools they’re given to accomplish that,” said Matt. “I am eager to show clinical research sites how the Slope eCSCM platform will ensure they have the clinical supplies needed for every subject visit to provide a positive patient experience.”

“Today, the complexity and scale of clinical trials is increasing, making it difficult for collaborators—sponsors, CROs, research sites, labs, suppliers—to keep these trials on schedule and within budget,” said Ben. “The industry knows that supply chain delays can delay trials and strain budgets for sponsors. I look forward to demonstrating how effectively coordinating, communicating, and controlling the procurement, shipping, receipt, and storage of clinical supplies with an eCSCM platform will result in a traceable chain of custody that will ease biological sample reconciliation and get their life-saving treatment to market faster.”

“We established long ago that one of Slope’s keys to success would be to hire a leadership team with strong life sciences industry domain expertise,” said Rust Felix, Slope CEO and cofounder. “We view being able to attract two industry veterans like Matt and Ben as a major win for, not only Slope, but our customers and the industry as a whole.”

Ben Carmel Joins Slope As Chief Revenue Officer
Ben Carmel Joins Slope as Chief Revenue Officer

More about Ben Carmel: Over Ben’s 17-year career, he has demonstrated a passion for collaborating with the life sciences industry to find real solutions to the challenges that impact healthcare. Ben began his career with Accenture, which led him to Polaris and IQVIA to help drive the adoption of innovative technology solutions within the life sciences community. For the last two years, he was responsible for global sales at H1, provider of the largest global healthcare network to help life sciences companies engage with healthcare professionals, clinical researchers, and sites.

More about Matt Smith: Matt has a proven track record contributing to company growth and expansion with 20 years of leadership and business development in the clinical research, Software as a Service (SaaS), and communications industries. He has established a career working with clinical research sites at organizations including IBM Watson Health, Devana Solutions, and most recently as the Senior Director of Business Development within ICON, a global CRO, where he worked with leading research sites.
SourceSlope

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”